Alpha Tau Treats First Glioblastoma Patient Outside US, Expanding Brain Cancer Therapy Globally
DRTS has more than doubled off its 52-week low of $2.85.
Summary
Alpha Tau Medical successfully treated the first recurrent glioblastoma patient outside the United States with its Alpha DaRT therapy in Israel. This marks the first international clinical application of the company's brain-specific delivery system. This development expands the clinical footprint of Alpha DaRT into a new geography for glioblastoma, a highly aggressive brain cancer with limited treatment options, especially for recurrent cases. This follows recent positive interim results from the US REGAIN trial for recurrent glioblastoma and FDA clearance to complete enrollment for that trial.
At the time of this announcement, DRTS was trading at $9.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $882.7M. The 52-week trading range was $2.85 to $11.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.